Page 377 - Read Online

Page 12 of 19 Marasco et al. Hepatoma Res 2020;6:33 I http://dx.doi.org/10.20517/2394-5079.2020.01

Reviewed and approved the final manuscript as submitted: Marasco G, Colecchia A, Golfieri R, Festi D
All authors read and approved the final manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol
2018;69:182-236.
3. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting
antiviral agents. Hepatology 2020;71:44-55.
4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
5. Dufour JF, Greten TF, Raymond E, Roskams T, De T, et al. Clinical practice guidelines EASL - EORTC clinical practice guidelines:
management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol 2012;56:908-43.
6. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular
carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
7. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
Gastroenterology 2016;150:835-53.
8. Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, et al. Prognostic factors for hepatocellular carcinoma recurrence. World J
Gastroenterol 2014;20:5935-50.
9. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118
studies. J Hepatol 2006;44:217-31.
10. Zhou JY, Zhang L, Li L, Gu GY, Zhou YH, et al. High hepatitis B virus load is associated with hepatocellular carcinomas development in
Chinese chronic hepatitis B patients: a case control study. Virol J 2012;9:16.
11. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after
resection of hepatocellular carcinoma. Cancer 2000;89:500-7.
12. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of
hepatocellular carcinoma. Ann Surg 2000;232:10-24.
13. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic
recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
14. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-
200.
15. Qu LS, Liu JX, Zhu J, Lu CH. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis
B viral load. Ann Hepatol 2017;16:412-20.
16. Jung KS, Kim JH, Kim SU, Song K, Kim BK, et al. Liver stiffness value-based risk estimation of late recurrence after curative resection
of hepatocellular carcinoma: Development and validation of a predictive model. PLoS One 2014;9:e99167.
17. Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, et al. Role of liver and spleen stiffness in predicting the recurrence of
hepatocellular carcinoma after resection. J Hepatol 2019;70:440-8.